The purpose of this study is to evaluate the effectiveness of crocin in patients with metabolic disorders. This is a 8-week randomized and double-blind placebo controlled clinical trial. Sixty adult patients who will be diagnosed with early stage metabolic syndrome based on AHA 2009 guidelines will be randomly assigned into crocin (15 mg/BID) or control (placebo/BID) group. At the first visit for intervention study and end of treatment course, a blood sample will be drawn and the following factors will be measured; lipid profile ( LDL, TG, TC, HDL level), fasting blood sugar (FBS), inflammatory cytokines, including TNF-α, VEGF, EGF, INF-γ, and IL1-α, IL1-β, IL2, IL4, IL6, IL8, IL10, MCP-I and antibody HSP27 , pro-oxidants- antioxidants balance (PAB) and genetic and novel biomarkers of cardio - vascular disorders. In addition, the effect of crocin on the depression and anxiety of the subjects will be investigated. The crocin tablets contain 15 mg crocin (active ingredient), and Lactose and Avicel (as excipients). placebo has no crocin. The tablets are administered orally twice daily for eight weeks.